مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

384
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

136
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

BOTULINUM TOXIN TYPE A THERAPY IN MIGRAINE: PRECLINICAL AND CLINICAL TRIALS

Pages

  0-0

Abstract

 Introduction: BOTULINUM TOXIN TYPE A (BTX-A) has been reported to be effective for the therapy for migraine. The purpose of this study was to investigate the effect of BTX-A on the immunoreactive levels of calcitonin gene-related peptide (CGRP) and substance P (SP) in the jugular plasma and medulla oblongata of migraine in rats induced by NITROGLYCERIN (NTG), and then to evaluate and compare the effectiveness of fixed (muscle)-sites and acupoint-sites injection of BTX-A for migraine therapy of patients in a randomly controlled trial extending over four months.Materials and Methods: Rats with NTG-induced migraine were subcutaneously injected with vehicle or BTX-A (5 U/kg or 10 U/kg bodyweight). CGRP-and SP-like immunoreactivity (CGRP-LI and SP-LI) were determined by radioimmunoassay. In clinical trials, sixty patients respectively received BTX-A (2.5 U each site, 25 U per patient) at fixed-sites (group F, n=30) including occipitofrontalis, corrugator supercili, temporalis and trapezius or at acupoint-sites (group A, n=30) including EX-HN3, EX-HN5, GV20, GB8, GB20 and BL10.Results: Local BTX-A injection suppressed NTG-induced CGRP-LI and SP-LI levels in jugular plasma and oblongata. BTX-A injection for both groups with migraine significantly reduced the attack frequency, intensity, duration and associated symptoms. The efficacy of BTX-A for migraine in group A (93% improvement) was more significant than that in group F (83% improvement) (P<0.01).Conclusions: The evidence that BTX-A decreases NTG-induced CGRP-LI and SP-LI levels in trigeminovascular system suggests that BTX-A attenuates migraine by suppression of neuropeptide release. BTX-A injections for migraine at acupoint-sites and fixed-sites are effective. Acupoint-sites BTX-A administration shows more efficacy for migraine than fixed-sites application.

Cites

  • No record.
  • References

  • No record.
  • Cite

    APA: Copy

    SHAO, YU FENG, ZHANG, YI, ZHAO, PENGJUN, YAN, WEN JUN, KONG, XIANG PAN, FAN, LIN LAN, & HOU, YI PING. (2013). BOTULINUM TOXIN TYPE A THERAPY IN MIGRAINE: PRECLINICAL AND CLINICAL TRIALS. IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ), 15(10), 0-0. SID. https://sid.ir/paper/292747/en

    Vancouver: Copy

    SHAO YU FENG, ZHANG YI, ZHAO PENGJUN, YAN WEN JUN, KONG XIANG PAN, FAN LIN LAN, HOU YI PING. BOTULINUM TOXIN TYPE A THERAPY IN MIGRAINE: PRECLINICAL AND CLINICAL TRIALS. IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ)[Internet]. 2013;15(10):0-0. Available from: https://sid.ir/paper/292747/en

    IEEE: Copy

    YU FENG SHAO, YI ZHANG, PENGJUN ZHAO, WEN JUN YAN, XIANG PAN KONG, LIN LAN FAN, and YI PING HOU, “BOTULINUM TOXIN TYPE A THERAPY IN MIGRAINE: PRECLINICAL AND CLINICAL TRIALS,” IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ), vol. 15, no. 10, pp. 0–0, 2013, [Online]. Available: https://sid.ir/paper/292747/en

    Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button